[1] |
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
|
[2] |
赵雁林, 刘志敏. 结核病实验室标准化操作与网络建设. 北京: 人民卫生出版社, 2013.
|
[4] |
赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015: 88-100.
|
[5] |
Oudghiri A, Karimi H, Chetioui F, et al. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco. BMC Infect Dis, 2018,18(1):98. doi: 10.1186/s12879-018-3009-9.
doi: 10.1186/s12879-018-3009-9
URL
pmid: 29486710
|
[6] |
Mok JH, Kang BH, Lee T, et al. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design. J Korean Med Sci, 2017,32(4):636-641. doi: 10.3346/jkms.2017.32.4.636.
doi: 10.3346/jkms.2017.32.4.636
URL
pmid: 28244290
|
[7] |
Smith SE, Ershova J, Vlasova N, et al. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010. Emerg Infect Dis, 2015,21(6):1002-1011. doi: 10.3201/eid2106.141907.
URL
pmid: 25988954
|
[8] |
Varghese B, Al-Hajoj S. First insight into the fluoroquinolone and aminoglycoside resistance of multidrug-resistant Mycobacterium tuberculosis in Saudi Arabia. Am J Trop Med Hyg, 2017,96(5):1066-1070. doi: 10.4269/ajtmh.16-0579.
doi: 10.4269/ajtmh.16-0579
URL
pmid: 28500800
|
[9] |
王海英, 王燕, 于春宝, 等. 2004—2007年山东省部分结核分枝杆菌耐药情况检测分析. 预防医学论坛, 2008,14(12):1075-1076,1080. doi: 10.3969/j.issn.1672-9153.2008.12.007.
|
[10] |
赵妮娜, 陈慧, 赵静, 等. 苏州地区532例结核病患者结核分枝杆菌对抗结核药物的耐药情况及其相关影响因素分析. 抗感染药学, 2019,16(10):1683-1687. doi: 10.13493/j.issn.1672-7878.2019.10-006.
|
[11] |
杨仪, 谢汉彬, 郑崇辉, 等. 汕头市耐多药肺结核患者二线药敏试验结果分析. 国际医药卫生导报, 2013,19(10):1424-1426. doi: 10.3760/cma.j.issn.1007-1245.2013.10.013.
|
[12] |
Jugheli L, Bzekalava N, de Rijk P, et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother, 2009,53(12):5064-5068. doi: 10.1128/AAC.00851-09.
doi: 10.1128/AAC.00851-09
URL
pmid: 19752274
|
[13] |
Dijkstra JA, van der Laan T, Akkerman OW, et al. In vitro susceptibility of Mycobacterium tuberculosis to amikacin, kanamycin, and capreomycin. Antimicrob Agents Chemother, 2018,62(3):e01724-17. doi: 10.1128/AAC.01724-17.
doi: 10.1128/AAC.01724-17
URL
pmid: 29311078
|
[14] |
Engström A, Perskvist N, Werngren J, et al. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2011,66(6):1247-1254. doi: 10.1093/jac/dkr109.
doi: 10.1093/jac/dkr109
URL
pmid: 21427106
|
[15] |
孙勇, 邢青, 张治国, 等. 北京地区对卷曲霉素和阿米卡星耐药结核分枝杆菌的rrs和tlyA基因突变研究. 中国防痨杂志, 2015,37(6):616-621. doi: 10.3969/j.issn.1000-6621.2015.06.009.
|
[16] |
Sowajassatakul A, Prammananan T, Chaiprasert A, et al. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiol, 2014,14:165. doi: 10.1186/1471-2180-14-165.
doi: 10.1186/1471-2180-14-165
URL
pmid: 24953243
|
[17] |
Wang H, Zhang X, Luo T, et al. Prediction of XDR/pre-XDR tuberculosis by genetic mutations among MDR cases from a hospital in Shandong, China. Tuberculosis (Edinb), 2014,94(3):277-281. doi: 10.1016/j.tube.2014.03.005.
|
[18] |
王洁, 陆俊梅, 黄晓辰, 等. 微量MIC检测判断结核分枝杆菌药敏的方法学研究. 中华检验医学杂志, 2010,33(4):315-319. doi: 10.3760/cma.j.issn.1009-9158.2010.04.006.
|
[19] |
陈军. 武汉地区结核分枝杆菌药物敏感性及氟喹诺酮耐药分子机制的研究. 武汉: 华中科技大学, 2011.
|